Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer ; volume:15 ; number:1 ; day:23 ; month:6 ; year:2017 ; pages:1-16 ; date:12.2017
BMC medicine ; 15, Heft 1 (23.6.2017), 1-16, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Tomar, Tushar
- Contributor
-
Alkema, Nicolette G.
Schreuder, Leroy
Meersma, Gert Jan
De Meyer, Tim
Van Criekinge, Wim
Klip, Harry G.
Fiegl, Heidi
Van Nieuwenhuysen, Els
Vergote, Ignace
Widschwendter, Martin
Schuuring, Ed
van der Zee, Ate G. J.
de Jong, Steven
Wisman, G. Bea A.
SpringerLink (Online service)
- DOI
-
10.1186/s12916-017-0870-0
- URN
-
urn:nbn:de:1111-2017101311280
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tomar, Tushar
- Alkema, Nicolette G.
- Schreuder, Leroy
- Meersma, Gert Jan
- De Meyer, Tim
- Van Criekinge, Wim
- Klip, Harry G.
- Fiegl, Heidi
- Van Nieuwenhuysen, Els
- Vergote, Ignace
- Widschwendter, Martin
- Schuuring, Ed
- van der Zee, Ate G. J.
- de Jong, Steven
- Wisman, G. Bea A.
- SpringerLink (Online service)
Other Objects (12)
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
High-grade serous ovarian cancer: the clone wars
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
High-grade serous ovarian cancer: the clone wars
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
High-grade serous ovarian cancer: the clone wars
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial